. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2015 May 11;24(7):1061–1070. doi: 10.1158/1055-9965.EPI-14-1355

Table 3.

Associations with cytokine polymorphisms among cases and controls with body mass index data.

	DLBCL^a			FL^a			CLL/SLL^a			Lymphoid Neoplasms^a
	Case/Control	OR^b	95%CI	Case/Control	OR^b	95%CI	Case/Control	OR^b	95%CI	Case/Control	OR^b	95%CI
TNF -308G→A (rs1800629)
no of studies=9^c	1477/4752	χ²=12.9	p_het=0.11	1176/4752	χ²=4.22	p=0.84	875/3576	χ²=13.5	p_het=0.04	4979/4752	χ²=11.3	p_het=0.19
GG	951/3322	1	ref	827/3322	1	ref	594/2525	1	ref	3319/3322	1	ref
GA/AA	513/1371	1.24	1.07–1.44	344/1371	0.95	0.86–1.06	271/1000	1.08	0.87–1.34	1616/1371	1.14	1.02–1.27
LTA 252A→G (rs909253)
no of studies=9^c	1510/4879	χ²=19.3	p_het =0.01	1184/4879	χ²=2.11	p_het =0.98	888/3694	χ²=10.2	p_het =0.12	5067/4879	χ²=11.0	p_het =0.20
AA	620/2201	1	ref	544/2021	1	ref	371/1701	1	ref	2161/2201	1	ref
AG/GG	877/2617	1.15	0.95–1.40	634/2617	0.93	0.87–0.99	507/1941	1.14	0.99–1.31	2860/2617	1.08	0.98–1.18
IL10 –3575T→A (rs1800890)
no of studies=9^c	1515/5061	χ²=19.5	p_het =0.01	1160/5061	χ²=6.57	p_het =0.58	883/3895	χ²=5.61	p_het =0.47	5015/5061	χ²=14.6	p_het =0.07
TT	430/1559	1	ref	324/1559	1	ref	231/1136	1	ref	1375/1559	1	ref
TA/AA	1072/3442	1.08	0.87–1.35	830/3442	1.15	1.04–1.28	642/2708	0.91	0.80–1.04	3595/3442	1.07	0.95–1.22
IL10 –1082A→G (rs1800896)
no of studies=7^c	948/3328	χ²=4.25	p_het =0.64	779/3328	χ²=2.00	p_het =0.92	340/2161	χ²=5.94	p_het =0.20	2844/3328	χ²=4.66	p_het =0.59
AA	240/944	1	ref	199/944	1	ref	101/631	1	ref	744/944	1	ref
AG/GG	702/2339	1.14	1.00–1.31	576/2339	1.10	1.05–1.15	236/1494	0.98	0.72–1.35	2077/2339	1.11	1.03–1.20
CARD15 Ex11–35→C (rs2066847)
no of studies=6^c	1261/4092	χ²=3.26	p_het =0.66	972/4092	χ²=12.6	p_het =0.03	735/2645	χ²=2.65	p_het =0.45	4267/4092	χ²=3.71	p_het =0.59
−−	1199/3098	1	ref	937/3098	1	ref	703/2530	1	ref	4081/3098	1	ref
−+/++	51/138	1.25	1.01–1.56	32/138	1.06	0.48–2.36	23/83	1.28	0.79–2.08	147/138	1.17	0.92–1.49
IL1A –889C→T (rs1800587)
no of studies=4^c	778/2082	χ²=1.49	p_het =0.68	634/2082	χ²=2.63	p_het =0.45	234/1601	χ²=2.77	p_het =0.25	2195/2082	χ²=3.83	p_het =0.28
CC	396/998	1	ref	311/998	1	ref	108/770	1	ref	1082/998	1	ref
CT/TT	377/1054	0.90	0.80–1.00	320/1054	0.96	0.81–1.13	124/808	1.09	0.80–1.48	1096/1054	0.95	0.84–1.08
IL1B –31C→T (rs1143627)
no of studies=4^c	769/2099	χ²=5.99	p_het =0.11	633/2099	χ²=6.28	p_het =0.10	232/1621	χ²=2.65	p_het =0.27	2188/2099	χ²=5.08	p_het =0.17
CC	340/922	1	ref	284/922	1	ref	107/730	1	ref	988/922	1	ref
CT/TT	423/1147	0.97	0.75–1.26	346/1147	0.96	0.75–1.23	123/868	0.98	0.70–1.37	1182/1147	0.96	0.83–1.11
IL2 –384T→G (rs2069762)
no of studies=4^c	770/2085	χ²=4.83	p_het =0.19	635/2085	χ²=2.40	p_het =0.49	232/1604	χ²=2.30	p_het =0.32	2185/2085	χ²=4.70	p_het =0.20
TT	388/1007	1	ref	309/1007	1	ref	112/775	1	ref	1062/1007	1	ref
TG/GG	376/1048	0.93	0.79–1.09	323/1048	0.99	0.85–1.15	118/806	1.03	0.80–1.33	1105/1048	1.00	0.86–1.16
IL6 –174G→C (rs1800795)
no of studies=4^c	772/2095	χ²=3.77	p_het =0.29	640/2095	χ²=4.70	p_het =0.20	234/1620	χ²=2.71	p_het =0.26	2203/2095	χ²=2.13	p_het =0.55
GG	271/703	1	ref	222/703	1	ref	81/541	1	ref	777/703	1	ref
GC/CC	495/1362	0.94	0.79–1.12	415/1362	0.94	0.73–1.21	151/1056	0.92	0.66–1.22	1408/1362	0.93	0.83–1.03
IL1B –511C→T (rs16994)
no of studies=3^c	708/1695	χ²=6.77	p_het =0.03	542/1695	χ²=2.99	p_het =0.22	136/1217	χ²=0.01	p_het =0.92	1843/1695	χ²=3.96	p_het =0.14
CC	311/733	1	ref	247/733	1	ref	67/543	1	ref	832/733	1	ref
CT/TT	392/934	0.98	0.71–1.35	292/934	0.92	0.74–1.14	68/653	0.84	0.59–1.20	996/934	0.94	0.79–1.12
IL1RN 9589A→T (rs454078)
no of studies=3^c	478/1598	χ²=5.75	p_het =0.06	422/1598	χ²=2.78	p_het =0.25	231/1598	χ²=2.07	p_het =0.36	1673/1598	χ²=3.98	p_het =0.14
AA	250/885	1	ref	210/885	1	ref	105/885	1	ref	849/885	1	ref
AT/TT	224/691	1.16	0.88–1.53	209/691	1.26	0.96–1.65	124/691	1.50	1.17–1.91	808/691	1.22	1.01–1.48
IL6 –597G→A (rs1800797)
no of studies=3^c	488/1591	χ²=3.99	p_het =0.14	421/1591	χ²=0.08	p_het =0.96	233/1591	χ²=2.17	p_het =0.34	1679/1591	χ²=0.31	p_het =0.86
GG	169/536	1	ref	160/536	1	ref	85/536	1	ref	615/535	1	ref
GA/AA	315/1031	0.95	0.71–1.28	258/1031	0.81	0.78–0.85	146/1031	0.87	0.67–1.12	1048/1031	0.87	0.82–0.93

DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; CLL/SLL: chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Odds ratios (OR) and 95% confidence intervals (CI) estimated using logistic regression adjusted for sex, age and study.

Tests for heterogeneity between studies were conducted using the likelihood ratio test to compare the model with an interaction term between the cytokine and study variables with the basic model which adjusted for study. For FL, EpiLymph- France and Spain were considered together due to small numbers of cases in some strata. Fewer studies had data for CLL/SLL (7 studies with TNF-308G>A, LTA252A>G or IL10-3575T>A data; 5 studies with IL10-1082A>G or CARD15 Ex11–35→C data; 3 studies with IL1A-889C>T, IL1B-31C>T, IL2-384T>G or IL6-174G>C data; and 2 studies with IL1B-511C>T data).